Browse News
Filter News
Found 65 articles
-
Organicell Regenerative Medicine, Inc. Announces Additions to Board of Directors
10/11/2022
Organicell Regenerative Medicine, Inc. announced that the Company has added independent board members to its board of directors.
-
Organicell Regenerative Medicine, Inc. Announces Expansion of Management Team
9/20/2022
Organicell Regenerative Medicine, Inc. (OTCQB:OCEL), a clinical-stage biopharmaceutical company focused on the development of innovative biological therapeutics and regenerative medicine, announced that the Company has recruited a new Chief Operating Officer, Chief Information Officer, and Director of Finance.
-
Organicell Regenerative Medicine, Inc. Announces Expansion into Health and Beauty Market
9/16/2022
Organicell Regenerative Medicine, Inc. announced today that the Company will expand into the skincare and haircare industries.
-
Organicell Regenerative Medicine, Inc. Closes $5.5 Million Funding Round
8/26/2022
Organicell Regenerative Medicine, Inc. (OTCQB:OCEL), a clinical-stage biopharmaceutical company principally focused on the development of innovative regenerative medicine and biological therapeutics, has closed its previously announced $4.0 million capital raise at $0.02 and corporate restructuring transaction.
-
Exosome Technologies Market Size, Share, Trends, Report 2022-2030
8/2/2022
According to report study, the global exosome technologies market valued at US$ 31 Mn in 2020 and projected to hit US$ 300 million by 2030, expanding growth at a CAGR of 23.5% from 2021 to 2030.
-
Organicell Announces Matt Sinnreich as CEO
7/26/2022
Organicell Regenerative Medicine, Inc . (OTCQB:OCEL), a clinical-stage biopharmaceutical company principally focusing on the development of innovative biological therapeutics in the extracellular vesicle space, announced today that the board of directors has appointed Matt Sinnreich as Chief Operating Officer and acting CEO.
-
Organicell Regenerative Medicine, Inc. Secures $4 Million in Funding for Clinical Trials and Agrees To Restructure Management
7/20/2022
Organicell Regenerative Medicine, Inc . announced today that it has secured $4.0 million in funding to finance clinical trials of its products and for general working capital purposes.
-
Organicell Regenerative Medicine, Inc. Provides Updates of Clinical Trial Activities
12/29/2021
Organicell Regenerative Medicine, Inc. is pleased to provide its stockholders and the investment community with the following updates regarding its approved Investigational New Drug Applications and other clinical trial related activities surrounding Zofin.
-
Organicell Regenerative Medicine, Inc. Uplist Of Common Stock To OTCQB Approved
11/9/2021
Organicell Regenerative Medicine, Inc. Uplist Of Common Stock To OTCQB Approved
-
Codiak has two engineered exosome programs in Phase I, each showing different types of engineering possibilities to deliver targeted payloads that pharmaceutical companies haven’t managed to push all the way through the clinic.
-
New therapeutic modalities always face an uphill climb, but the urgency of COVID-19 may have opened the door for two related ones: cell therapies and exosomes.
-
Exosome Technologies Market: Rise in Prevalence of Chronic Diseases to Drive Global Market
8/10/2021
According to the report, the global exosome technologies market was valued over US$ 31 Mn in 2020 and is projected to expand at a CAGR of ~24% from 2021 to 2031.
-
Organicell Announces FDA Approval Of IND Application For The Use Of Zofin™ In COVID-19 Long Haulers
7/21/2021
Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced today that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for its lead product, Zofin™, for the treatment of 'Prolonged COVID-19 Symptoms' ("Long Haulers").
-
Please check out the biopharma industry's COVID-19 stories that are trending for June 15, 2021.
-
Organicell Announces Positive Results of Their Expanded Access Trial for the Treatment of Mild to Moderate COVID-19 Using ZofinTM
6/15/2021
Organicell Announces Positive Results of Their Expanded Access Trial for the Treatment of Mild to Moderate COVID-19 Using Zofin TM.
-
Organicell Launches Autologous Blood Derived Platform PPX™ – Patient Pure X™
6/9/2021
Organicell Launches Autologous Blood Derived Platform PPX ™ – Patient Pure X ™
-
Clinical Catch-Up: May 24-28
6/1/2021
Heading into the U.S. Memorial Day holiday weekend and the official start of summer, it was a moderately busy week for clinical trial news. Take a look. -
Gene therapy is still very much cutting-edge with the potential to cure incurable genetic diseases. Here’s some recent news in the space.
-
Organicell To Present Results Of Zofin™ Clinical Studies At The International Society Of Cell And Gene Therapy Annual Meeting
5/25/2021
Organicell To Present Results Of Zofin ™ Clinical Studies At The International Society Of Cell And Gene Therapy Annual Meeting
-
Organicell Signs an Exclusive Distribution Agreement with Apex Services in Pakistan
5/19/2021
Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, today announced that it has signed an exclusive distribution agreement with Apex Services Pakistan to import and distribute Zofin TM to hospitals and clinics in the country.